Joining Michael today is Brigette Bard, the founder and CEO of BioSure UK, helping the country return to normality with its rapid COVID-19 testing. When the world was disrupted by the pandemic, BioSure moved quickly – having already pioneered self-testing technology with the first easy-to-use HIV home testing kit. With a mission to give people confidence and control over their own health, BioSure is paving the way for ground-breaking innovation in the medical space.
Founder and CEO of BioSure UK, Brigette Bard has carved a successful, entrepreneurial career in the FMCG sector. Based on her experience with pregnancy testing, she is passionate about the role self-testing has to play in allowing people to make informed choices and assume responsibility for their own healthcare. She is actively and dynamically involved in normalising the conversation around HIV, HIV tests, breaking down stigma and nurturing understanding around confident sex and sexual health. BioSure develops, manufactures, sources and distributes rapid tests with the highest levels of accuracy, many rivalling those of standard laboratory tests. Its rapid diagnostic and detection tests are invaluable tools where immediate results are the primary consideration. The tests that it manufactures and supplies are used worldwide for the management of human infectious disease.